MX2022015242A - Uso de 2-hidroxibencilamina (2-hoba) para tratar la aterosclerosis. - Google Patents

Uso de 2-hidroxibencilamina (2-hoba) para tratar la aterosclerosis.

Info

Publication number
MX2022015242A
MX2022015242A MX2022015242A MX2022015242A MX2022015242A MX 2022015242 A MX2022015242 A MX 2022015242A MX 2022015242 A MX2022015242 A MX 2022015242A MX 2022015242 A MX2022015242 A MX 2022015242A MX 2022015242 A MX2022015242 A MX 2022015242A
Authority
MX
Mexico
Prior art keywords
hoba
treat atherosclerosis
atherosclerosis
treat
acellerated
Prior art date
Application number
MX2022015242A
Other languages
English (en)
Inventor
Sean S Davies
Macrae F Linton
Olivier Boutaud
Original Assignee
Univ Vanderbilt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Vanderbilt filed Critical Univ Vanderbilt
Publication of MX2022015242A publication Critical patent/MX2022015242A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Gear Processing (AREA)

Abstract

Un método para tratar la aterosclerosis acelerada por hipercolesterolemia familiar en un sujeto que lo necesite, que comprende administrar una cantidad eficaz de un depurador de dicarbonilo.
MX2022015242A 2020-06-01 2021-06-01 Uso de 2-hidroxibencilamina (2-hoba) para tratar la aterosclerosis. MX2022015242A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063033127P 2020-06-01 2020-06-01
PCT/US2021/035314 WO2021247620A1 (en) 2020-06-01 2021-06-01 Use of 2-hoba to treat atherosclerosis

Publications (1)

Publication Number Publication Date
MX2022015242A true MX2022015242A (es) 2023-01-11

Family

ID=78829877

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015242A MX2022015242A (es) 2020-06-01 2021-06-01 Uso de 2-hidroxibencilamina (2-hoba) para tratar la aterosclerosis.

Country Status (9)

Country Link
US (1) US20230364032A1 (es)
EP (1) EP4157243A4 (es)
JP (1) JP2023529130A (es)
CN (1) CN116157118A (es)
AU (1) AU2021285836A1 (es)
BR (1) BR112022024523A2 (es)
CA (1) CA3180792A1 (es)
MX (1) MX2022015242A (es)
WO (1) WO2021247620A1 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2320387A1 (de) * 1973-04-21 1974-10-31 Boehringer Mannheim Gmbh Phenoxyalkylcarbonsaeurederivate und verfahren zur herstellung derselben
EP1471152A1 (en) * 2003-04-25 2004-10-27 Institut National De La Sante Et De La Recherche Medicale (Inserm) Mutations in the human PCSK9 gene associated to hypercholesterolemia
EP3615015B1 (en) * 2017-04-27 2024-03-13 Vanderbilt University Gamma-ketoaldehyde scavengers for treating atherosclerosis

Also Published As

Publication number Publication date
CN116157118A (zh) 2023-05-23
US20230364032A1 (en) 2023-11-16
BR112022024523A2 (pt) 2023-01-24
JP2023529130A (ja) 2023-07-07
EP4157243A1 (en) 2023-04-05
WO2021247620A1 (en) 2021-12-09
CA3180792A1 (en) 2021-12-09
AU2021285836A1 (en) 2023-02-02
EP4157243A4 (en) 2024-06-12

Similar Documents

Publication Publication Date Title
NZ755166A (en) Biofilm disrupting composition for use on chronic wounds
EA201690745A1 (ru) Способы лечения и предотвращения болезни "трансплантат против хозяина"
MX2022000027A (es) Extracto de ca?amo para tratamiento del dolor, cancer y epilepsia en animales.
MY162903A (en) Methods of treatment of pancreatic cancer
GB201114051D0 (en) Compounds and their uses
ZA202300875B (en) Kat6 inhibitor methods and combinations for cancer treatment
MX2007008764A (es) Metodos para tratar capsulitis adhesiva.
MX348941B (es) Medios y metodos para trata y/o prevenir el cancer dependiente del ligando natural de receptor de aril-hidrocarburo.
JOP20220054A1 (ar) علاج اعتلال الدماغ syngap1
MX2021010025A (es) Tratamiento de lesión renal.
MX2017015012A (es) Formulaciones tópicas y orales que comprenden taurina y magnesio para la prevención y el tratamiento del acné.
EA202091640A1 (ru) Способы лечения опосредованного il-6 воспаления без иммунодепрессии
MX2022015900A (es) Inhibidores de alk2 para el tratamiento de la anemia.
MX2020011817A (es) Metodos para tratar el linfoma.
MX2023000187A (es) Dosificacion de vibegron para el tratamiento de vejiga sobreactiva.
MX2020006224A (es) Metodos y terapia combinada para el tratamiento del cancer.
MX2022007113A (es) Inhibidores de la desmetilasa de la histona especifica de la lisina para el tratamiento de las neoplasias mieloproliferativas.
MX2022010258A (es) Composiciones y métodos para tratar la lesión renal.
MX2023006551A (es) Tratamiento de las convulsiones refractarias.
MX2021008716A (es) Metodo para tratar dolor de osteoartritis al administrar resiniferatoxina.
MX2021004709A (es) Metodo y medicamento para tratar cancer insensible a inhibidor de se?alizacion de pd-1/pd-l1.
MX2019012659A (es) Metodos para tratar ateroesclerosis con neutralizadores gamma-cetoaldehido.
MX2022015242A (es) Uso de 2-hidroxibencilamina (2-hoba) para tratar la aterosclerosis.
MX2023006651A (es) Tratamiento de la hemofilia con fitusirán.
MX2023001328A (es) Compuestos de tiofeno para su uso en el tratamiento de la fibrosis renal.